Parexel, Parexel Announce Multi-year Strategic Partnership To Leverage AI To Help Enhance And Accelerate Delivery Of Safe And Effective Clinical Trials
Portfolio Pulse from Benzinga Newsdesk
Parexel and Palantir Technologies have announced a multi-year strategic partnership to enhance and accelerate clinical trials using AI. Parexel will use Palantir's Foundry and AIP to improve its clinical data platform, aiming to boost trial efficiency and safety. This marks the first time a CRO collaborates with Palantir in such a capacity, expanding on their year-long cooperation.
April 25, 2024 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palantir Technologies enters a strategic partnership with Parexel to apply its AI technology for improving clinical trials, potentially boosting its visibility and use in the healthcare sector.
The partnership with Parexel represents a significant application of Palantir's technology in the healthcare sector, potentially leading to increased adoption and visibility of its AI and data analytics platforms. This strategic move could positively impact Palantir's stock in the short term as it showcases the company's expansion and utility in healthcare, a critical and growing industry.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90